BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors. Sasaki-Saito N, Yamamura K, Hitaka T, Hirano Y, et al. J Dermatol 2022 Oct 11. doi: 10.1111/1346-8138.16592.

Read + Share

Amedeo Smart

Independent Medical Education

Sasaki-Saito N, Yamamura K, Hitaka T, Hirano Y, et al. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors. J Dermatol 2022 Oct 11. doi: 10.1111/1346-8138.16592.
PMID: 36217799